Aminolevulinic acid/sodium ferrous citrate

Drug Profile

Aminolevulinic acid/sodium ferrous citrate

Alternative Names: 5-ALA-SFC; Sodium ferrous citrate/aminolevulinic acid; SPP-003

Latest Information Update: 24 Mar 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator SBI Pharmaceuticals Co Ltd
  • Developer SBI Pharmaceuticals Co Ltd; University of Tokyo
  • Class Amino acids; Antianaemics; Antineoplastics; Keto acids; Levulinic acids; Oxidants; Small molecules
  • Mechanism of Action Erythropoiesis stimulants; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II Chemotherapy-induced anaemia
  • Clinical Phase Unknown Type 2 diabetes mellitus
  • Preclinical Malaria

Most Recent Events

  • 10 Jul 2015 SBI Pharmaceuticals completes its phase II trial in Chemotherapy-induced anaemia in Japan (UMIN000012812)
  • 10 Jan 2015 Phase-II clinical trials in Chemotherapy-induced anaemia in Japan (PO) (UMIN000012812)
  • 01 Jul 2014 Clinical trials in Type-2 diabetes mellitus (In adults, In the elderly) in Bahrain (PO) (NCT02481141)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top